139 related articles for article (PubMed ID: 9815593)
21. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells.
Tsang WP; Kwok TT
Oncogene; 2007 Jul; 26(33):4877-81. PubMed ID: 17297456
[TBL] [Abstract][Full Text] [Related]
22. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1.
Chen YB; Yan ML; Gong JP; Xia RP; Liu LX; Li N; Lu SC; Zhang JG; Zeng DB; Xie JG; Yang JY; Yan LN
Chin Med J (Engl); 2007 Apr; 120(8):703-7. PubMed ID: 17517188
[TBL] [Abstract][Full Text] [Related]
23. Involvement of CtBP1 in the transcriptional activation of the MDR1 gene in human multidrug resistant cancer cells.
Jin W; Scotto KW; Hait WN; Yang JM
Biochem Pharmacol; 2007 Sep; 74(6):851-9. PubMed ID: 17662696
[TBL] [Abstract][Full Text] [Related]
24. Promoter methylation of glutathione S-transferase pi1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression.
Gao P; Yang X; Xue YW; Zhang XF; Wang Y; Liu WJ; Wu XJ
Cancer; 2009 Jul; 115(14):3222-32. PubMed ID: 19484794
[TBL] [Abstract][Full Text] [Related]
25. Intravitreal daunomycin induces multidrug resistance in proliferative vitreoretinopathy.
Esser P; Tervooren D; Heimann K; Kociok N; Bartz-Schmidt KU; Walter P; Weller M
Invest Ophthalmol Vis Sci; 1998 Jan; 39(1):164-70. PubMed ID: 9430558
[TBL] [Abstract][Full Text] [Related]
26. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
Punyammalee B; Manoromana S; Purisa W; Chariyalertsak S; Rerkamnuaychok B
J Med Assoc Thai; 1997 Sep; 80 Suppl 1():S162-73. PubMed ID: 9347665
[TBL] [Abstract][Full Text] [Related]
27. Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line.
Baas F; Jongsma AP; Broxterman HJ; Arceci RJ; Housman D; Scheffer GL; Riethorst A; van Groenigen M; Nieuwint AW; Joenje H
Cancer Res; 1990 Sep; 50(17):5392-8. PubMed ID: 1974823
[TBL] [Abstract][Full Text] [Related]
28. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer.
Campling BG; Young LC; Baer KA; Lam YM; Deeley RG; Cole SP; Gerlach JH
Clin Cancer Res; 1997 Jan; 3(1):115-22. PubMed ID: 9815546
[TBL] [Abstract][Full Text] [Related]
29. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA.
Lincke CR; van der Bliek AM; Schuurhuis GJ; van der Velde-Koerts T; Smit JJ; Borst P
Cancer Res; 1990 Mar; 50(6):1779-85. PubMed ID: 1968359
[TBL] [Abstract][Full Text] [Related]
30. Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics.
Kobayashi H; Takemura Y; Miyachi H
Hum Cell; 2001 Sep; 14(3):172-84. PubMed ID: 11774737
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs.
Baker EK; Johnstone RW; Zalcberg JR; El-Osta A
Oncogene; 2005 Dec; 24(54):8061-75. PubMed ID: 16091741
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
[TBL] [Abstract][Full Text] [Related]
33. Reversal of P-glycoprotein-mediated multidrug resistance with small interference RNA (siRNA) in leukemia cells.
Peng Z; Xiao Z; Wang Y; Liu P; Cai Y; Lu S; Feng W; Han ZC
Cancer Gene Ther; 2004 Nov; 11(11):707-12. PubMed ID: 15375375
[TBL] [Abstract][Full Text] [Related]
34. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.
Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y
Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441
[TBL] [Abstract][Full Text] [Related]
35. A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line.
Bhat UG; Winter MA; Pearce HL; Beck WT
Mol Pharmacol; 1995 Oct; 48(4):682-9. PubMed ID: 7476894
[TBL] [Abstract][Full Text] [Related]
36. [Pharmacological control of P-glycoprotein expression].
Muller C; Bailly JD; Jaffrezou JP; Goubin F; Laurent G
Bull Cancer; 1994 May; 81(5):386-91. PubMed ID: 7749215
[TBL] [Abstract][Full Text] [Related]
37. Retrovirus-mediated transfer of anti-MDR1 hammerhead ribozymes into multidrug-resistant human leukemia cells: screening for effective target sites.
Kobayashi H; Takemura Y; Wang FS; Oka T; Ohnuma T
Int J Cancer; 1999 Jun; 81(6):944-50. PubMed ID: 10362143
[TBL] [Abstract][Full Text] [Related]
38. [Multidrug resistance in chronic lymphocytic leukemia].
Szendrei T; Magyarlaki T; Kovács G; Nagy A; Szomor A; Molnár L; Dávid M; Tokés-Füzesi M; Rideg O; Pótó L; Pajor L; Kajtár B; Losonczy H
Orv Hetil; 2008 Jan; 149(4):161-7. PubMed ID: 18201958
[TBL] [Abstract][Full Text] [Related]
39. Methylation of WTH3, a possible drug resistant gene, inhibits p53 regulated expression.
Tian K; Wang Y; Huang Y; Sun B; Li Y; Xu H
BMC Cancer; 2008 Nov; 8():327. PubMed ID: 18992151
[TBL] [Abstract][Full Text] [Related]
40. Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer.
Raguz S; Randle RA; Sharpe ER; Foekens JA; Sieuwerts AM; Meijer-van Gelder ME; Melo JV; Higgins CF; Yagüe E
Int J Cancer; 2008 Mar; 122(5):1058-67. PubMed ID: 17955490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
